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Bile acids, synthesized from cholesterol by the liver, are chemically transformed along the intestinal 
tract by the gut microbiota and the products of these transformations signal through host receptors, 
impacting overall host health. These transformations include bile acid deconjugation, oxidation, 
and 7a-dehydroxylation. An understanding of the biogeography of bile acid transformations in the 
gut is critical because deconjugation is a prerequisite for 7a-dehydroxylation and because most gut 
microorganisms harbor bile acid transformation capacity. Here, we used a coupled metabolomic 
and metaproteomic approach to probe in vivo activity of the gut microbial community in a 
gnotobiotic mouse model. Results revealed the involvement of Clostridium scindens in 7a-
dehydroxylation, of the genera Muribaculum and Bacteroides in deconjugation, and of six 
additional organisms in oxidation (the genera Clostridium, Muribaculum, Bacteroides, 
Bifidobacterium, Acutalibacter and Akkermansia). Furthermore, the bile acid profile in mice with 
a more complex microbiota, with a dysbiosed microbiota or with no microbiota was considered. 
For instance, conventional mice harbor a large diversity of bile acids, but treatment with an 
antibiotic such as clindamycin results in complete inhibition of 7a-dehydroxylation, underscoring 
the strong inhibition of organisms able to carry out this process by this compound. Finally, 
comparison of the hepatic bile acid pool size as a function of microbiota revealed that a reduced 
microbiota affects host signaling but not necessarily bile acid synthesis. In this study, bile acid 
transformations were mapped to the associated active microorganisms, offering a systematic 
characterization of the relationship between microbiota and bile acid composition.  
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The gut is a complex ecosystem hosting a wide diversity of microorganisms. The gut microbiome 
is sometimes referred to as the forgotten endocrine organ because of its profound influence on host 
physiology. Gut microbes convert dietary and other exogenous molecules into signaling 
metabolites to communicate with the host1. Bile acids (BAs) are one of these microbiota-derived 
signaling metabolites.  
Primary bile acids are synthesized in the liver from cholesterol (dietary or endogenous). In the 
hepatocytes, they are conjugated to glycine or taurine and stored continuously in the gall bladder 
as the main component of bile. The human liver synthesizes only two primary bile acids: cholic 
acid (CA) and chenodeoxycholic acid (CDCA), while the rodent liver synthesizes five: CA, CDCA, 
two muricholic acids (αMCA and βMCA) and ursodeoxycholic acid (UDCA), the 7b epimer of 
CDCA2. After food intake, the presence of fat molecules in the duodenum stimulates the release of 
a hormone, cholecystokinin, which triggers the contraction of the gall bladder and the relaxation of 
the Oddi sphincter, leading to the release of bile into the small intestine3. Along the intestinal tract, 
primary bile acids undergo several chemical transformations that are catalyzed by gut 
microorganisms, leading to the formation of secondary bile acids. Thus, the activity of the gut 
microbiota increases the diversity of the bile acid pool. The microbial transformation of the bile 
acid pool is essential as it modifies their detergent properties (i.e., their cytotoxicity) and also their 
affinity for host bile acid receptors2. For instance, the secondary bile acids deoxycholic acid (DCA) 
and lithocholic acid (LCA), resulting from microbial 7α-dehydroxylation of CA and CDCA, have 
a higher affinity for the membrane receptor Takeda G-protein receptor 5 (TGR5) compared to the 
















Gut microorganisms act on the side chain, the hydroxyl groups, as well as the cyclohexane rings in 
the bile acid structure. Thus, microbial bile acid transformations include deconjugation or 
hydrolysis (i.e., the removal of the taurine/glycine moiety on the side chain), oxidation and 
epimerization of hydroxyl groups (at the C3, C7, and C12 positions) and of the C5-hydrogen, 
reduction of ketone groups, dehydroxylation at C7 and C126, desulfation7, esterification of 
hydroxyl groups8, and the oxidation of a steroid ring to form unsaturated bile acids9,10 (Figure 1). 
Recently, a new microbial bile acid transformation was identified in both humans and mice: 
reconjugation. After being deconjugated by bacteria carrying bile salt hydrolase (BSH), the 
unconjugated bile acid can be reconjugated by bacteria with amino acids such as tyrosine, 
phenylalanine, leucine forming tyrosocholic acid, phenylalanocholic acid, and leucocholic acid 
respectively11. 
 
The abundance and diversity of bacteria carrying out the various bile acid transformations vary 
enormously. Deconjugating bacteria, synthesizing BSH, are reported to be abundant in the gut and 
widespread across bacterial phyla12,13. Similarly, oxidation of the hydroxyl groups in bile acids is 
also a common activity in gut microorganisms and is catalyzed by hydroxysteroid dehydrogenases 
(HSDHs)14. In contrast, 7α-dehydroxylating bacteria are considered as rare organisms in the gut 
and so far, only belong to the order Clostridiales15. The 7α-dehydroxylation reaction is catalyzed 
by a series of proteins (Bai proteins) encoded by genes belonging to the bai operon16. However, 
deconjugation is a prerequisite for bile acid 7α-dehydroxylation, thus the importance of considering 
the relative localization of these two bile acid transformations17,18.  
 
Connecting the spatial organization of the gut microorganisms to biological function remains 
challenging because of the high diversity of the gut microbial community19. For bile acid 
transformations, this difficulty is compounded by the large number of bile acid chemical species 















biogeography dates back to 1968, when Midtvedt and Norman sampled luminal content along the 
intestinal tract of three rats and probed for in vitro bile acid transformations in each sample20. First, 
they noticed variability in the distribution of microbial bile acid transformations amongst the three 
rats. For instance, one rat had very little deconjugating activity in the small intestine (ileum) 
compared to the two other rats. Two rats showed 7α-HSDH activity (oxidation of the 7α-hydroxyl) 
in the ileum while the third rat did not. Since then, other studies have investigated bile acid profiles 
longitudinally21,22. However, probing for the presence/absence of specific bile acids may not 
accurately reflect the in vivo microbial bile acid transformation activity nor the presence/absence 
of the organisms responsible for the synthesis of that particular bile acid. For instance, it was 
recently observed that bile acid 7α-dehydroxylation activity was absent in the ileum of gnotobiotic 
mice despite colonization of the 7α-dehydroxylating organism, Clostridium scindens23. It was 
hypothesized that the high level of tauro-conjugated bile acids in the ileum likely precluded bile 
acid 7α-dehydroxylation23. Furthermore, the ability to transform bile acids in vitro does not 
necessarily reflect the in vivo activity. For instance, Narushima et al., reported that the 7α-
dehydroxylating bacterium Clostridium hiranonis (formerly Clostridium strain TO-931), known to 
deconjugate TCA to CA and to 7α-dehydroxylate cholic acid in vitro did not show any activity 
when amended to germ-free mice24. Thus, in vivo studies are needed to identify organisms active 
in bile acid metabolism within the microbial community of the gut. 
In this study, we explored the longitudinal distribution of bile acid transformations in gnotobiotic 
mouse models and identified the microorganisms responsible for these transformations using a 
combined metabolomic and metaproteomic approach. Bile acid 7α-dehydroxylation was a 
transformation of particular interest because of its connection to TGR5 signaling. We contrasted 
gnotobiotic mice lacking bile acid 7α-dehydroxylating activity with gnotobiotic mice containing 
the same base microbiota but complemented with the 7α-dehydroxylating organism Clostridium 















either a complex microbiota (conventional, specific pathogen-free (SPF) mice), a reduced 















Material and Methods 
 
Animal experiments 
Groups of age-matched C57BL/6 mice (6–12 weeks old) were used. Germ-free (GF) and 
gnotobiotic sDMDMm2 mice were established and maintained at the Clean Mouse Facility of the 
Department of Clinical Research of the University of Bern. sDMDMm2 mice were colonized with 
a mouse-intestine derived 12-species mouse microbiota (Oligo-MM12) (Table S1)25. All Oligo-
MM12 strains are available at http://www.dsmz.de/miBC. In-depth description of the Oligo-MM12 
consortium species and description of novel taxa are provided elsewhere26–28. SPF mice were 
purchased from Envigo (formerly Harlan) and acclimatized to the local animal facility for 7 days 
before the start of experiments. SPF mice were pretreated with the antibiotic clindamycin (100µL 
by intra-peritoneal injection, 2 mg/mL in PBS) or streptomycin (100 µL by gavage, 200 mg/mL in 
PBS) 24h before sacrifice. sDMDMm2 mice were inoculated with C. scindens ATCC 35704 by 
gavage of 107-9 CFU of C. scindens and colonized for 7 days before sacrifice. C. scindens pre-
colonization was performed in flexible film isolators. These mice are denoted sDMDMm2+Cs. 
 
All animals were sacrificed inside a sterile laminar flow hood and aseptic technique was used to 
collect the specific tissues and contents (liver, terminal ileum tissue, distal duodenum content, 
ileum content, cecum content and colon content). The collected samples were flash-frozen in liquid 
nitrogen and kept at -80°C to await subsequent analyses. All animal experiments were performed 
in accordance with the Swiss Federal and the Bernese Cantonal regulations and were approved by 
the Bernese Cantonal ethical committee for animal experiments under the license numbers BE 















Quantitative Real-Time PCR 
Liver (30 mg of the caudate lobe) and terminal ileum tissue were lysed and homogenized in tubes 
filled with 2.8 mm zirconium oxide beads using Precellys 24 Tissue Homogenizer (Bertin 
Instruments) at 6,500 rpm for 3x10 sec. Total RNA was isolated with the RNeasy Plus Mini Kit 
(QIAGEN). QuantiTect Reverse Transcription Kit (QIAGEN) was used to synthesized 20 µL 
cDNA templates from 1 µg of purified RNA. cDNA templates were diluted 10x before use in 
subsequent reactions. SensiFAST SYBR No-ROX Kit (Bioline) was used for quantitative real-time 
PCR with a final reaction volume of 10 µL (7.5 µL of mix and 2.5 µL of diluted cDNA template). 
Gene-specific primers (400nM) were used in each reaction and all results were normalized to the 
ribosomal protein L32 mRNA (primers sequences can be found in Table S2). PCR product 
specificity was verified by performance of a melting curve for each primer set. Assays were 
performed using Mic qPCR Cycler (Bio Molecular Systems) with a three-step program (2 min 
95°C, followed by 40 cycles of 95°C for 5 s, 60°C for 10 s and 72 °C for 10 s). Four replicates of 
each sample for each primer set were performed, as well as negative controls (no reverse 
transcription and no template controls). Relative Quantification analysis using the REST method 
was performed with the Mic qPCR analysis software (Bio Molecular Systems).  
 
Preparation of Bile Acid Standard Solutions 
Stock solutions (10 mM) of each BA standard were prepared in methanol (Table S3). Individual 
standard solutions (100 µM) were mixed together and diluted with a 50:50 (v/v) mix of ammonium 
acetate (5 mM) and methanol to construct external standard curves between 1 and 10,000 nM. 
Deuterated CDCA and DCA were used as recovery standards. 
 
Bile acid extraction 
Approximately 10 mg of freeze-dried intestinal sample was homogenized with 150 µL of H2O and 















oxide beads. Homogenization was performed using an automated Precellys 24 Tissue Homogenizer 
(Bertin Instruments) at 5,000 rpm for 20 s. Mixed samples were equilibrated on ice for 1 h. A 
volume of 500 µL of ice-cold alkaline acetonitrile (5% ammonia in acetonitrile) was added to the 
homogenates, which were then vigorously vortexed, and continuously shaken for 1 h at room 
temperature. The mixtures were centrifuged at 16,000 x g for 10 min and the supernatants collected. 
The pellets were extracted with another 500 µL of ice-cold alkaline acetonitrile. Supernatants from 
the two extractions steps were pooled and lyophilized in a rotational vacuum concentrator (Christ) 
before reconstitution in 100 µL of a 50:50 (v/v) mix of ammonium acetate [5 mM] and methanol 
at pH 6, and stored at −20°C. Supernatants were diluted according to the intestinal compartment 
(4,000-fold for the small intestine and liver samples and 100-fold for the cecum and colon samples) 
before LC-MS injection. The extraction recovery ratios ranged between 75 and 85%. 
 
Ultra-High-Pressure Liquid Chromatography-High Resolution Mass Spectrometry Analyses. 
Both qualitative and quantitative analyses were conducted on an Agilent 6530 Accurate-Mass Q-
TOF LC/MS mass spectrometer coupled to an Agilent 1290 series UHPLC system (Agilent). The 
separation was achieved using a Zorbax Eclipse-Plus C18 column (2.1 × 100 mm, 1.8 μm; Agilent) 
heated at 50°C. A binary gradient system consisted of 5 mM ammonium acetate pH 6 in water as 
eluent A and acetonitrile as eluent B. The sample separation was carried out at 0.4 mL/min over a 
22 min total run time using the following program: 0–5.5 min, isocratic 21.5% B; 5.5–6 min, 21.5–
24.5% B; 6–10 min, 24.5–25% B; 10–10.5 min, 25–29% B; 10.5–14.5 min, isocratic 29% B; 14.5–
15 min, 29–40% B; 15–18 min, 40–45% B; 18–20.5 min, 45–95% B, 20.5–22 min, isocratic 95%.  
The system was re-equilibrated to initial conditions for 3 min. The sample manager system 
temperature was maintained at 4°C and the injection volume was 5 μL. Mass spectrometer detection 
was operated in negative ionization mode using the Dual AJS Jet stream ESI Assembly. The QTOF 
instrument was operated in the 4 GHz high-resolution mode (typical resolution 17,000 (FWHM) at 















Internal calibration was performed during acquisition via continuous infusion of a reference mass 
solution [5 mM purine, 1 mM HP-921 (Agilent reference mass kit) in 95% MeOH acidified with 
0.1% formic acid] and allowed to permanently achieve a mass accuracy better than 5 ppm. HR 
mass spectra were acquired over the range of m/z 300– 700 at an acquisition rate of three spectra/s. 
AJS settings were as follows: drying gas flow, 8 L/min; drying gas temperature, 300◦C; nebulizer 
pressure, 35 psi; capillary voltage, 3500 V; nozzle voltage, 1000 V; fragmentor voltage, 175 V; 
skimmer voltage, 65 V; octopole 1 RF voltage, 750 V. Data was processed using the MassHunter 
Workstation (Agilent). According to this method, 36 bile acids (Table S3) were quantified by 
external calibration curves. Extracted ions chromatograms (EIC) were based on a retention time 
(RT) window of ±0.5 min with a mass- extraction-windows (MEW) of ±30 ppm centered on m/ztheor 
of each bile acid. 
 
Bile acid-metabolizing enzyme database 
Whole genomes for the 12 Oligo-MM12 species28 and C. scindens ATCC 3570417 were obtained 
from the NCBI and EBI (Accession numbers available in Table S4). Sequences were processed by 
Prodigal29 to produce the gene sequences forming the BLASTP search database. Reference protein 
sequences for BSH, 3α-HSDH, 3β-HSDH, 7α-HSDH, 7β-HSDH, 12α-HSDH proteins were 
obtained from NCBI via the accession numbers presented in Table S5. These sequences were 
subsequently blasted against the produced protein database. The top 5 matches, as identified by bit 
score were selected for manual review. The final sequences with the highest scores were selected 
and are presented in Table S6. 
 
Metaproteome analysis  
Proteins were extracted from small intestine, cecum and colon content samples of sDMDMm2 
(n=3) and sDMDMm2+Cs mice (n=3) at the Oak Ridge National Laboratory (Oak Ridge, TN, 















as described previously30 with slight modifications. Briefly, intestinal content samples were 
suspended in SDS lysis buffer (4% SDS, 100 mM Tris-HCl, 10 mM dithiothreitol, pH 8.0) and 
subjected to bead-beating. The proteins were isolated by chloroform-methanol extraction and 
resuspended in 4% sodium deoxycholate (SDC) in 100 mM ammonium bicarbonate (ABC) buffer. 
The crude protein concentration was estimated using a Nanodrop (Thermo Fisher Scientific). 
Protein samples (250 μg) were then transferred to a 10 kDa MWCO spin filter (Vivaspin 500, 
Sartorius), washed with ABC buffer, and digested with sequencing-grade trypsin. 
After proteolytic digestion, the tryptic peptide solution was adjusted to 1% formic acid to 
precipitate the remaining SDC. The precipitated SDC was removed using water-saturated ethyl 
acetate. For each sample, 9 μg of peptides were analyzed by automated 2D LC-MS/MS using a 
Vanquish UHPLC with autosampler plumbed directly in-line with a Q Exactive Plus mass 
spectrometer (Thermo Fisher Scientific) across three successive salt cuts of ammonium acetate (35, 
100 and 500 mM), each followed by a 155-minute organic gradient. Eluting peptides were 
measured and sequenced by data-dependent acquisition on the Q Exactive Plus as described 
earlier31. 
 
Peptide identification and protein inference were performed as follows: MS raw data files were 
searched against the protein database of 12 bacterial species genomes published by Garzetti et al. 
(2017)28 and the C. scindens ATCC 35704 genome published by Devendran et al. (2019)17 (Table 
S4) along with common contaminates (e.g., trypsin, human keratin) appended with a decoy 
database consisting of reverse protein sequences to control the false-discovery rate (FDR) to 1% at 
the spectral level32.  
 
MS/MS spectra data analysis (searching and filtering) was done by Crux mass spectrometry 
analysis toolkit (Crux version: 3.2-f7929ba)33. Tide-search34 was used for searching. For Tide-















methionine, allowed 4 missed-cleavages, a precursor mass tolerance of 10 parts per million (ppm), 
a static modification on cysteines (iodoacetamide; +57.0214 Da), dynamic modifications on 
methionine (oxidation; +15.9949), and a fragment ion mass tolerance of 0.02 Da. Trypsin was used 
as the digestion enzyme that cleaves C-terminal to arginine and lysine residues with an exception 
of proline in C-terminal to lysine and arginine. The obtained search result was processed by 
Percolator35 to estimate q values using default parameters. MS1-level precursor intensities were 
derived from moFF36 using default parameters along with match between runs features from 
biological replicates. An FDR cutoff of 1% was used as the peptide level. Protein intensities were 
calculated by summing together FDR-filtered quantified peptides, and normalized by performing 
LOESS and median central tendency procedures on log2-transformed values by InfernoRDN37. All 
proteins that had at least one unique peptide sequence were retained for biological interpretation. 
The list of proteins obtained along with their intensities is available in Supplemental Table S7.  
All raw mass spectra for the proteome measurements have been deposited into the 
ProteomeXchange repository with the following accession numbers: (MassIVE Accession: 
MSV000084484, ProteomeXchange: PXD015971, FTP link to 

















Results and Discussion 
 
Mapping bile acid transformations in gnotobiotic mice 
 
The first goal of this study was to explore, using a combined metabolomic and metaproteomic 
approach, the longitudinal distribution of bile acid transformations in gnotobiotic mouse models 
(sDMDMm2 and sDMDMm2 + C. scindens) and to identify the microorganisms responsible for 
these transformations.  
 
a) Bile salt deconjugation is an active transformation in the large intestine 
Bile salt deconjugation (hydrolysis) constitutes the first step in the microbial bile acid metabolism 
(Figure 1)13. For instance, 7α-dehydroxylation requires unconjugated bile acids18, while other  
processes such as dehydrogenation (oxidation) have been reported to occur with conjugated bile 
acid14,38.  
In the small intestine, the amendment of C. scindens to the Oligo-MM12 microbial community led 
to a decrease in the deconjugating activity. Indeed, in the jejunum of C. scindens-colonized 
gnotobiotic mice, not only was the concentration of the dominant unconjugated primary BA 
(βMCA) 8-fold lower as compared to that in the sDMDMm2 cohort in absolute terms, but also, the 
ratio of βMCA to its conjugated counterpart (TβMCA) was 16-fold lower than in the microbiota 
lacking C. scindens (Figure 2). Accordingly, bile salt hydrolase (BSH) peptides were not detected 
in the small intestine of C. scindens-colonized gnotobiotic mice (Figure 3). In contrast, BSH 
expression was detected in all compartments in the sDMDMm2 cohort. Together, the bile acid 
profile and the BSH protein expression data suggest decreased BSH activity in the small intestine 
in the presence of C. scindens (Figures 2 and 3). This could be due either to differences in 
microbiota colonization of the gut or, more directly, to changes in the expression of the BSH 















intestine between the two gnotobiotic mouse models (e.g., Blautia coccoides YL58 and Clostridium 
clostridioforme YL32, Figure 4). However, protein abundance of the small intestine BSH-producer 
M. intestinale YL27 is comparable between C. scindens-colonized mice and the control group 
(sDMDMm2 mice) (Figure 4). Thus, we hypothesize that expression of BSH enzymes is 
diminished in the C. scindens-colonized mice relative to the control.   
 
In the large intestine of the two gnotobiotic mouse models, deconjugated bile acids predominate 
and BSH are detected, suggesting active bile salt hydrolysis in this compartment (Figures 2 and 3). 
In contrast to the small intestine, the protein abundance composition is comparable between the 
two gnotobiotic mouse models in the cecum and colon for all 12 strains (Figure 4). 
 
While seven of the twelve organisms in the Oligo-MM12 microbiota harbor BSH-encoding genes 
(Table S6), BSHs from only two organisms, Muribaculum intestinale YL27 and Bacteroides 
caecimuris I48, were detected in the metaproteome (Figure 3 and Table S8). Thus, we propose that 
these two organisms are the main bile salt hydrolyzing strains in this mouse model. The BSH of M. 
intestinale YL27 is highly expressed along the entire intestinal tract of sDMDMm2 animals, while 
the BSH of B. caecimuris I48 was detectable only in the colon in both types of gnotobiotic mice 
(Figure 3).  
Thus, based on the bile acid profile and the metaproteomic data of gnotobiotic mice (both 
sDMDMm2 and C. scindens-colonized sDMDMm2), we show that bile salt hydrolysis activity is 
mainly extant in the large intestine (Figures 2 and 3).  
 
b) Bile acid oxidation is the most widespread transformation in the intestinal tract 
Another common microbial bile acid transformation is oxidation (dehydrogenation), producing bile 
acids such as 3-oxoCA or 7-oxoDCA (Figure 1). There are several hypotheses regarding the role 















reduces its toxicity for the host and the microbiota39. Thus, it could be considered a detoxification 
process. Second, it is also hypothesized that oxo- groups could serve as electron sinks14. Reduction 
of these oxo- groups would result in a net consumption of two electrons which would be favorable 
for fermenting bacteria in the anoxic environment of the large intestine, which is lacking in 
electrons acceptors40. 
 
Hydroxysteroid dehydrogenases (HSDH) catalyze the oxidation and epimerization of hydroxyl 
groups in the bile acid structure (Figure 1). Thirty-two predicted HSDHs were found in the genomes 
of the Oligo-MM12 species and C. scindens. They include 3a-HSDH (oxidation of 3a-OH and 
reduction of 3-oxo group), 3b-HSDH (oxidation of 3b-OH and reduction of 3-oxo group), 7a-
HSDH (oxidation of 7a-OH and reduction of 7-oxo group), 7b-HSDH (oxidation of 7b-OH and 
reduction of 7-oxo group) and 12a-HSDH (oxidation of 12a-OH and reduction of 12-oxo group) 
(Figure 1 and Table S6). Only 9 out of 32 predicted HSDHs were detected with the metaproteomic 
analysis (Figure 3, Tables S6 and S8) and corresponded exclusively to 3a-HSDH, 7a-HSDH, and 
7b-HSDH (thus missing 3β-HSDH and 12α-HSDH). Furthermore, the bile acid profiles of 
gnotobiotic mice suggest that microbial oxidation of BAs only takes place in the large intestine 
(Figure 2).  
 
Indeed, oxo- bile acids were not detected in the small intestine (Figure 2) despite the presence of 
7β-HSDH from C. innocuum I46 in sDMDMm2 mice and of 3α-HSDH from B. caecimuris I48 in 
C. scindens-colonized sDMDMm2 mice (Figure 3, Table S8). We could speculate that the oxygen 
gradient41 along the intestinal tract may have impacted the activity of the HSDH in vivo, but further 
research should be carried out to test this hypothesis. Hirano and Masuda (1981) reported that 
oxygen inhibited the activity of the 7α-HSDH of Eubacterium lentum (currently known as 















level in the small intestine might inactivate its activity, precluding the formation of 7-oxo bile acids. 
However, oxygen sensitivity has never been reported for 3α-HSDH.  
 
The metaproteomic analysis revealed that 7 species of the Oligo-MM12 as well as C. scindens were 
producers of 3α-HSDH and/or 7α/β-HSDH in the intestinal tract of the gnotobiotic mice (Figure 3, 
Table S8).  
Interestingly, the amendment of C. scindens clearly decreased the expression of 3α-HSDH in vivo. 
In the original gnotobiotic mice, 3α-HSDH from Acutalibacter muris KB18, Akkermansia 
muciniphila YL44 and B. caecimuris I48 were present in the large intestine, while in the mice 
amended with C. scindens, only the one from B. caecimuris I48 was detected (Figure 3).  
In contrast, the amendment of C. scindens enhanced the expression of 7α/β-HSDHs. The 7β-HSDH 
from Bifidobacterium animalis YL2 and the 7α-HSDH from C. scindens were observed only in the 
metaproteome of C. scindens-colonized animals. Additionally, in both cohorts, the 7α-HSDHs from 
M. intestinale YL27 and B. caecimuris I48, as well as the 7β-HSDH from C. clostridioforme YL32 
were encountered. These findings demonstrate that a single strain can profoundly alter the bile acid 
composition and expression of bile acid-metabolizing enzymes within a given microbial 
community. The remaining question is whether C. scindens affected the expression of enzymes 
directly or impacted the abundance of certain species. Previously, Studer et al. (2016) observed 
only minor changes in the fecal Oligo-MM12 microbiota composition following the addition of C. 
scindens43. These minor changes included a decrease in abundance of A. muris KB18 that could 
explain the absence of 3α-HSDH from this species in C. scindens-colonized cohort (Figure 3). 
However, the protein abundance for the 12 Oligo-MM12 species is comparable in the large intestine 
of the two gnotobiotic mouse model, suggesting that the amendment of C. scindens has little impact 
on the large intestine microbial community (Figure 4). 
Furthermore, Devendran and colleagues (2019) reported a downregulation, by the secondary bile 















them, baiA2 (HDCHBGLK_01433) encodes a 3α-HSDH44. We hypothesize that C. scindens-
specific metabolites, such as 7-dehydroxylated secondary bile acids (e.g., DCA), may affect the 
expression of bile acid-metabolizing enzymes by other bacteria of the Oligo-MM12 consortium. 
The non-detection of 3α-HSDH associated with A. muris KB18 and A. muciniphila YL44 in 
gnotobiotic mice colonized with C. scindens (Figure 3) supports this hypothesis. Interestingly, 3β-
HSDH were entirely absent in the metaproteome. Consistent with this result, iso- bile acids were 
not detected in the gnotobiotic animals (Figures 1 and 2). 12α-HSDH were also lacking in the 
metaproteome despite the presence of 12-oxoLCA in C. scindens-colonized mice (Figure 2). C. 
scindens is known to carry a gene encoding a 12α-HSDH and could be an active producer of 12-
oxoLCA in vivo. Marion et al., (2018) reported the formation of 12-oxoLCA in vitro and proposed 
it as a transient intermediate of CA 7α-dehydroxylation by C. scindens23. Here, we hypothesize that 
12α-HSDH from C. scindens is present in too low an abundance to be detected with metaproteomic 
analysis. In line with this hypothesis, the other enzymes of the 7α-dehydroxylation pathway were 
absent in the metaproteome despite the clear presence of 7α-dehydroxylated secondary bile acids 
(Figure 2).	
	
c) Bile acid 7α-dehydroxylation is restricted to the large intestine 
The bile profile in the large intestine is very similar for mice models with and without C. scindens, 
with the exception of the presence of 7α-dehydroxylated species in the model including C. scindens 
(Figure 2). The 7α-dehydroxylated species detected include LCA, DCA and MDCA 
(murideoxycholic acid), the conjugated form of the latter two (TDCA and TMDCA), as well as 7α-
















Amongst enzymes of the 7α-dehydroxylation pathway, only the 7α-hydroxy-3-oxo-Δ4-cholenoic 
acid oxidoreductase (BaiCD)45 was detected in the colon of C. scindens-colonized cohort. None of 
the Bai enzymes were detected in the small intestine samples of these mice (Figure 3, Table S8). 
Based on the metaproteomic and metabolomic data, we show that bile acid 7α-dehydroxylation 
occurs only in the large intestine of mice colonized with C. scindens (Figures 2 and 3). This 
observation supports an earlier study in which the large intestine was demonstrated to be the 
ecological niche of C. scindens in the gnotobiotic sDMDMm2 mouse model23. 
 
While all 12 microorganisms within the Oligo-MM12 microbiota harbor bile acid-modifying 
enzymes (Table S6), peptides from only 7 of them were detected that mapped onto bile acid-related 
enzymes (Figure 3, Table S8).  Because the metaproteomic approach is limited in measurement 
dynamic range, we cannot rule out the activity of the 5 other strains but can conclude that these 7 
are the most active in bile acid transformations.  
	
The second goal of the study was to assess the impact of the microbiota on the bile acid pool. To 
tackle this, we compared the bile acid pools of gnotobiotic mice to ones of mouse models with 
various gut microbiota complexities: a very complex microbiota (SPF), a reduced microbiota 
(antibiotic-treated SPF), or the absence of microbiota (germ-free). 
	
The microbiota shapes the bile acid pool composition 
 
Germ-free mice are devoid of microbial bile acid transformations. Thus, their bile acid pool is 
exclusively composed of liver-derived tauro-conjugated primary bile acids (Figures 5 and S2). TCA 
and TβMCA dominate the bile acid pool in all compartments (i.e., they represent ≈94% of the liver 















liver, a small fraction of unconjugated βMCA (836±544 nmol/g of tissue) is also noted along with 
very minor contributions (<10nmol/g of content) of the αMCA and βMCA in some intestinal 
compartments (ileum, cecum and colon). These observations support an earlier study from Sayin 
et al (2013)21 who also observed minor fractions of unconjugated MCAs in germ-free mice. We 
hypothesize that the high bile acid synthesis activity in the liver does not allow for conjugating 
enzymes to act on all of the newly synthesized BA, resulting in the release into the intestine of a 
fraction of primary bile acids that have escaped conjugation in the liver. As expected, secondary 
bile acids are altogether absent in the GF mouse intestine due to the dearth of microorganisms.  
 
For comparison, we also considered SPF animals with or without antibiotic treatment. As expected, 
SPF mice exhibited the highest bile acid diversity (Figure 5). Secondary bile acids in SPF mice are 
present in the small intestine, while in C. scindens-bearing gnotobiotic animals, they were detected 
only in the large intestine (Figures 2 and 5). As the mouse liver is able to re-conjugate deconjugated 
BA, tauro-conjugated 7α-dehydroxylated bile acids (TMDCA, THDCA, TDCA, TωMCA) are 
observed in the upper intestinal tract. Thus, it is not possible to determine whether the 7α-
dehydroxylated bile acids DCA and HDCA in the small intestine come from 7α-dehydroxylation 
of CA and HCA (the 6α epimer of αMCA) or from the deconjugation of TDCA and THDCA in 
that compartment (Figure 5).  
 
In contrast to the other models, secondary bile acids represent more than half of the bile acid pool 
in the large intestine of SPF mice and the conjugated bile acids are present at low levels (Figure 
S2). Additionally, 7α-dehydroxylated secondary bile acids, comprising the 7-dehydroxylated form 
of the primary bile acids (DCA, LCA, MDCA, HDCA), the oxidized species (12oxoLCA, 3-
oxoLCA, 6-oxoLCA, 6-oxo-alloLCA) and the epimerized species (isoLCA, alloLCA), represent 















produce iso-bile acid (3β-epimers), allo-bile acids (5α-epimers), and 6β-epimers (e.g., HCA) in the 
large intestine (Figure 5).  
 
Antibiotic treatment had a tremendous impact on bile acid transformation throughout the intestinal 
tract. In the small intestine, bile acid diversity was extremely reduced compared to that in untreated 
SPF mice (Figure 5). The most salient impacts are the suppression of bile acid deconjugation in the 
small intestine and the complete abolition of 7α-dehydroxylation by the clindamycin treatment 
(Figure 5). Streptomycin-treated animals exhibited decreased amounts of 7α-dehydroxylated 
species but this antibiotic was not as efficient as clindamycin at inhibiting 7α-dehydroxylation, 
suggesting the survival of 7α-dehydroxylating bacteria to streptomycin treatment (Figure S1). 
Interestingly, tauroconjugated 7α-dehydroxylated species (TMDCA and THDCA) were detected 
in the small intestine (Figure 5). We attribute the presence of those species to the 7-dehydroxylation 
of MCAs (α-, β-, ω-MCA) and HCA prior to the antibiotic treatment, followed by recycling via the 
enterohepatic circulation and reconjugation in the liver before release into the small intestine.  
 
7α-dehydroxylated bile acids have been linked to protection against Clostridioides difficile 
infections (CDI) through the inhibitory role of 7-dehydroxylated BAs in C. difficile spore 
germination and outgrowth46,47.  Based on the bile acid profile of clindamycin- and streptomycin-
treated mice (Figures 5 and S1), it would be predicted that treatment with streptomycin is less of a 
risk factor for CDI as compared to that with clindamycin, and that 7α-dehydroxylating organisms 
are sensitive to clindamycin but not streptomycin. In accordance with these hypothesis, Theriot et 
al. (2016) showed that cecal content from mice treated with clindamycin triggers spore germination 
and cells outgrowth of C. difficile48. 
Furthermore, Slimings and Riley (2014) reported no association between the use of 
aminoglycosides (an antibiotic class that includes streptomycin) and CDI, while clindamycin was 















acquired) in patient meta-analyses49–51. Additionally, two of the major bile acid 7α-dehydroxylating 
organisms, C. scindens and C. hylemonae, are sensitive to clindamycin (Table S9). Furthermore, 
two studies observed that restricting the use of clindamycin led to a sustained decrease in CDI52,53. 
Buffie et al. (2015), observed that the cecal microbiota of SPF mice treated with clindamycin 
underwent profound losses of Lachnospiraceae, a family that includes several 7α-dehydroxylating 
strains (e.g., C. scindens and C. hylemonae)54. These observations are all consistent with 
clindamycin effectively inhibiting BA 7-dehydroxylation and thus, creating conditions propitious 
for the germination and outgrowth of C. difficile spores. These data support previous research that 
reported drastic changes in the fecal BA pool following antibiotic treatment48,55. The novelty of the 
present study is the extensive bile acid profile for the liver and four intestinal compartments 
(duodenum, ileum, cecum and colon). Other studies have focused on fewer sample type (liver and 
plasma samples55, or gallbladder and serum21, or ileum and cecum48). Furthermore, the number of 
bile acids screened in this study is greater compared to previous studies21,48,55, offering more in-
depth reporting of the impact of antibiotic treatment on bile acid composition. This study also 
reports for the first time the antibiotic susceptibility profiles of three major bile acid 7-
dehydroxylating species C. scindens, C. hylemonae and C. hiranonis (Table S9). 
 
Microbiota-host interactions regulate the bile acid pool size 
 
Supporting earlier research21, our data show that germ-free mice harbor an abundant bile acid pool 
(Figures 5 and S2). Here, we also observed that mouse models with a reduced microbiota 
(gnotobiotic and antibiotic-treated mice) have an increased hepatic bile acid pool compared to 
conventional mice (SPF) harboring a more diverse microbiota (Figure 6a). Furthermore, we noted 
a large inter-individual variability of the hepatic BA pool in GF and gnotobiotic mice cohorts 
compared to that in SPF and antibiotic-treated SPF mice (Figure 6a). This clearly indicates that BA 















In mammals, the nuclear receptor farnesoid X receptor (FXR), highly expressed in the ileum56, 
controls hepatic bile acid synthesis through a negative feedback loop57. The activation of FXR by 
bile acids induces the release of fibroblast growth factor 15 (Fgf15) in the intestine, which reaches 
the liver via portal vein circulation and inhibits the expression of the hepatic enzyme Cyp7a1 
(cholesterol 7α-hydroxylase), responsible for catalyzing the rate-limiting step in bile acid 
synthesis21.  
 
The tauro-conjugated murine primary BAs are strong antagonists of FXR58, while CDCA, and the 
7α-dehydroxylated species DCA and LCA are potent FXR agonists59, thus acting as repressors of 
bile acid synthesis. Gut microbes are important actors in FXR-mediated regulation of bile acid 
synthesis because they decrease the concentration of FXR antagonists (e.g., TβMCA, TαMCA) and 
produce unconjugated bile acids and secondary bile acids, which activate FXR21. The role of the 
deconjugating microbial community is particularly important as deconjugation contributes to a 
decrease in the concentration of the FXR antagonists TMCAs60 and allows further transformation 
such as 7α-dehydroxylation18. Germ-free mice, devoid of microbial bile acid transformations, have 
the largest bile acid pool size compared to that of other mice models harboring a microbial 
community (Figures 5 and S2). As previously demonstrated21, we observed that the concentration 
of TβMCA was high in germ-free mice, resulting from the absence of microbial deconjugation 
(Figure 5). Consequently, the FXR-dependent negative feedback loop was inhibited, resulting in 
increased bile acid synthesis21 and hepatic bile acid pool (Figure 6a). 
 
The ileal ratio of FXR antagonists (TMCAs) over FXR agonists59 
(CDCA+CA+TCDCA+TCA+DCA+LCA+TDCA+TLCA) is a good indicator of the size of the 
hepatic bile acid pool (Figure 6b). Indeed, this relationship offers an explanation as to why C. 
scindens-colonized sDMDMm2 mice have a higher bile acid pool size compared to sDMDMm2 















mice relative to mice lacking C. scindens (Figure 6b), explaining the higher bile acid synthesis. The 
increased ratio is likely due to reduced BSH activity in the small intestine, as is reflected in the 
metaproteomic data, with no BSH activity detected in the small intestine (Figure 3). The reduced 
BSH activity leads to an increased concentration of FXR antagonists (particularly TMCAs) in the 
ileum. Indeed, TβMCA level is 3-fold greater in the ileum of C. scindens-colonized cohort 
compared to that in the sDMDMm2 animals (Figure 2). Similarly to the hepatic BA pool, there is 
a large inter-individual variability in the ileal FXR antagonist/agonist ratio in germ-free and 
gnotobiotic cohorts compared to that in SPF and antibiotic-treated SPF mice (Figure 6b). This ileal 
ratio is relevant only for mouse studies as it takes into account the murine specific conjugated 
primary BA (TMCA) as FXR antagonists, which are absent in humans. In humans, very little is 
known about endogenous FXR antagonists. Only LCA has been reported to have an FXR antagonist 
activity in addition to a partial agonist activity in cells61. Further research is needed to investigate 
the ligand potency of human primary, secondary and tertiary bile acids towards the FXR receptor. 
 
Antibiotic treatment also affects BA deconjugating activity, and most likely, FXR signaling, 
leading to increased bile acid synthesis (Figure 6). In order to better understand the FXR-mediated 
regulation of bile acid synthesis by the gut microbiota, we measured the ileal expression of Fgf15 
and hepatic expression of Cyp7a1 in our mice models. Mice models with no or a reduced microbiota 
(GF, gnotobiotic and antibiotic-treated SPF) show a significantly reduced ileal expression of Fgf15 
(more than 10-fold) relative to SPF mice (Figure 6e).  
 
The expression of Cyp7a1 is significantly increased in antibiotic-treated mice compared to 
untreated ones (Figure 6d). In contrast, we did not detect a significant difference in Cyp7a1 
expression between GF and SPF as previously reported by Sayin et al. (2013). However, the 
increase reported by Sayin et al. (2013) is only 2-fold and could be considered minor when 















Cyp7a1 mRNA expression between GF and SPF with a chow diet62. Although not statistically 
significant, C. scindens-colonized mice show an increased Cyp7a1 expression compared to 
sDMDMm2 and GF mice which is consistent to the higher bile acid pool (Figure 6d).  
  
Altogether, these data show that having a reduced microbiota impacts FXR signalling (via the 
downregulation of Fgf15). Bile acid synthesis was mostly impacted by the antibiotic-mediated 
dysbiosis. There is a large inter-individual variation in the hepatic BA pool and ileal FXR 
antagonist / agonist ratio in germ-free and gnotobiotic mice (Figure 6a, b, c) which is not observed 
in SPF and antibiotic-treated mice. This suggest that the bile acid synthesis is more tightly regulated 
in mice harboring a more diverse microbial community.  
 
Bile acid detoxification  
Intestinal sulfated bile acids were measured in this study. Bile acid sulfation is a major host 
metabolic pathway to detoxify and eliminate bile acids. Sulfotransferases (e.g., Sult2a1) catalyze 
the sulfation (or sulfonation) of bile acids in the liver. Sulfation of BAs increases their solubility, 
reduces the intestinal absorption, and consequently fosters their urinary and fecal elimination. In 
humans, about 70% of the bile acid pool in the urine is sulfated but under pathological conditions 
(e.g., cholestatic diseases), the fraction of sulfated bile acid increases63.  
 
Sulfation in SPF mice is low compared to the germ-free, gnotobiotic and antibiotic-treated mouse 
models (Figures 2 and 5). In SPF mice, sulfated bile acids are not detected in the liver and the 
amount of sulfated BAs in the intestine are 2-fold smaller than those of the mouse models with a 
reduced microbial community (Figure 2 and 5). Miyata et al. (2006), reported that the hepatic 
sulfotransferase Sult2a1 is negatively regulated through FXR in mice and humans64. Sult2a8 was 















expression of Sult2a8 was comparable amongst the various mouse models, suggesting that Sult2a8 

















Bile acids exert crucial functions in the host that go beyond their role as lipid detergents and gut 
microbes play a central role in the bile acid metabolism. By modifying the structure of the bile acid, 
microorganisms influence their affinity to host bile acid receptors. In this study, we characterized 
the biogeography of bile acid transformation in gnotobiotic mice. We identify the main organisms 
involved in bile acid metabolism in a gnotobiotic mouse model and the localization of their activity 
in the gut. Furthermore, by comparing the bile acid profiles of mouse models with either reduced 
or more complex microbiota, we emphasized the profound influence of the gut microbial 
community on the regulation of the bile acid pool size and composition. Finally, by measuring the 
expression of Fgf15, Cyp7a1 and Sult2a8, we demonstrated that a reduced microbiota affects FXR 
signaling but not necessarily bile acid synthesis. The latter was mainly impacted by antibiotic-
mediated dysbiosis. Finally, we report that bile acid sulfonation by Sult2a8, the major BA 

















As indicated in the Material and Method section, all raw mass spectra for the proteome 
measurements have been deposited into the ProteomeXchange repository with the following 
accession numbers: (MassIVE Accession: MSV000084484, ProteomeXchange: PXD015971, FTP 
link to files: ftp://MSV000084484@massive.ucsd.edu, username: MSV000084484, Reviewer 
password: 'abcd1234'). All other data are either contained in the article or available upon request 
from the corresponding author.  
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Figure 1 | Microbial bile acid transformations. 
Deconjugation (bile salt hydrolysis), oxidation of hydroxyl groups, reduction of ketone group and 
bile acid 7α-dehydroxylation are major bile acid transformations occurring in the intestinal tract 
and are those on which we focused in this study. The enzymes catalyzing each transformation are 
indicated in red. Other microbial bile acid transformations (e.g., desulfation66, reconjugation11, the 
oxidation of C12-hydroxyl group on taurocholic acid by 12α-HSDH14,38) are not presented in this 

















































































Figure 2 | Bile acid composition along the intestinal tract of sDMDMm2 and C. scindens-
















































































































































































































































































































































































































































































































































































































































































and sDMDMm2 mice pre-colonized 7 days with C. scindens (n=5) were sacrificed and intestinal 
content samples were harvested and processed for bile acid LC-MS/MS measurements. Values 
indicate measured bile acid concentrations in nmol/g of tissue or intestinal content. Black bars 
indicate primary conjugated bile acids, teal bars secondary conjugated BAs, gray bars primary 
deconjugated BAs, yellow bars secondary BAs (all but 7-dehydroxylated), and blue bars represent 

















Figure 3 | Biogeography of specific bile-acid transformation enzymes and the associated 
microorganisms based on metaproteomic analysis. 
sDMDMm2 mice (n=3) and sDMDMm2 mice pre-colonized 7 days with C. scindens (n=3) were 
sacrificed and intestinal content samples were harvested and processed for metaproteomic analysis. 
Metaproteomes were mined to find homologous sequences of known bile salt hydrolases (BSH), 
3α/β-HSDH, 7α/β-HSDH and 12α-HSDH as well as C. scindens bai genes. A) Scheme illustrating 
where bile salt hydrolases, 3α-, 7α- and 7β-hydroxysteroid dehydrogenase (HSDH) and Bai 
enzymes are expressed in the gut and which are the bacterial species producing these enzymes. 
12α-HSDH and 3β-HSDH were not detected in the metaproteome, and therefore are not presented 
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triplicates (Table S8). The only one that was found in only 2 mice out of 3 is the 3a-HSDH from 
B. caecimuris I48 in the small intestine (Table S8). B) Venn diagrams summarizing the bile acid -
metabolizing enzymes detected in sDMDMm2 mice and C. scindens-colonized sDMDMm2 mice 
metaproteomes. For each enzyme detected, the strain producing the enzyme is indicated on the 
diagram, on the left or right circle if the enzyme was detected in sDMDMm2 mice or C. scindens-
colonized sDMDMm2, respectively. If an enzyme was found in both sDMDMm2 and C. scindens 





Figure 4 | Protein abundance along the intestinal tract of sDMDMm2 and C. scindens-colonized 
sDMDMm2 gnotobiotic mice based on the metaproteomic analysis of intestinal content. 
sDMDMm2 mice (n=3) and sDMDMm2 mice pre-colonized 7 days with C. scindens (n=3) were 
sacrificed and intestinal content samples were harvested and processed for metaproteomic analysis. Of 
note, proteins (2-4% of total) in the control mice were assigned to C. scindens ATCC 35704 and are not 
depicted in this figure. Contamination of control mice with C. scindens was evaluated experimentally 













































































relatedness, which is a current challenge in the field of metaproteomic. Using a more stringent approach 
(matched metaproteome database), we resolved this issue of genome relatedness and did not detect C. 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































treated SPF mice based on LC-MS/MS analysis. SPF mice were pre-treated with clindamycin 
24h before sacrifice. Intestinal content samples were harvested from GF mice (n=5), SPF mice 
(n=5), clindamycin-treated SPF mice (n=5). Samples were processed for bile acid LC-MS/MS 
measurements. Values indicate measured bile acid concentrations in nmol / g of tissue or intestinal 
content. Black bars indicate primary conjugated bile acids, teal bars secondary conjugated BAs, 
gray bars primary deconjugated BAs, yellow bars secondary BAs (all but 7-dehydroxylated), and 
















Figure 6 | Probing the influence of the gut microbiota on BA synthesis and detoxification. A) 
Hepatic bile acid pool. Each dot corresponds to an individual mouse. Histograms show the median 
of the hepatic bile acid pool for the mouse models considered. B) ileal FXR antagonist/agonist 
ratio. TαMCA, TβMCA were considered to be FXR antagonists and CDCA, CA, DCA, LCA, 
TCDCA, TCA, TDCA and TLCA, FXR agonists according to Parks et al. (1999)59. Each dot 
corresponds to an individual mouse. The horizontal bar in the scatter dot plot indicates the median 
for the mouse models considered. C) Correlation between the hepatic bile acid pool and the ileal 
FXR antagonist/agonist ratio. Each dot corresponds to an individual mouse. Pearson correlation 
analysis was computed with GraphPad Prism. D, E, F) Gene expression of Cyp7a1, Fgf15 and 
Sult2a8 in each mouse model considered relative to SPF mice (n=5 mice for each mouse model). 
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